- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02348385
Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers
Study Overview
Detailed Description
Aim 1:
To determine sex differences in amphetamine-induced dopamine (DA) release in healthy tobacco smokers and nonsmokers.
FLB-457 has been used in several PET centers and has recently been approved for use at the Yale University PET Center. We would like to determine whether there are sex differences in amphetamine induced DA release in healthy tobacco smokers and nonsmokers. Specifically, 40 healthy tobacco smokers and 40 healthy nonsmokers will have an magnetic resonance imaging (MRI) scan followed on another day by two FLB scans (ideally, the two PET scans will be carried out in the same day). Starting at 3 hours before the second PET scan, amphetamine (0.4mg/kg, PO) will be administered.
Aim 2:
To determine sex differences in amphetamine-induced dopamine release in tobacco smokers from Aim 1 after treatment with guanfacine. Guanfacine will be given under a different protocol. We plan to determine whether guanfacine treatment differentially inhibits amphetamine-induced DA release in men and smokers from Aim 1. After their first scan, the same 40 healthy tobacco smokers from Aim 1 will take guanfacine for 3 weeks under and then will have another set of FLB scans (ideally, the two PET scans will be carried out in the same day). Starting at 3 hours before the second PET scan, amphetamine (0.4mg/kg, PO) will be administered, as before. The sets of scans will be separated by at least 21 days, but due to scheduling and technical difficulties the second set may be scheduled up to 6 weeks after the first set.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
General inclusion criteria:
- men and women, aged 18-55 years
- who are able to read and write
- who are able to give voluntary written informed consent
- have no current uncontrolled medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology
- have no history of a neurological or psychiatric disorder, e.g., no DSM-IV Axis 1 diagnosis in 2 preceding years)
- drink less than 21 drinks/week for women and less than 35 drinks per week for men
- have not used marijuana in the past 30 days and have not met criteria for dependence in the past 2 years
- do not suffer from claustrophobia or any MRI contradictions
- to participate in imaging studies including 2 PET scans and 1 MRI scan
- nonsmokers (smoked < 100 cigarettes in lifetime with urinary cotinine levels 0-30 ng/mL both at intake evaluation and on scan day)
- smokers (smoked at least 10 cigarettes/day for at least one year with an Fagerstrom score (FTND)>3, urine cotinine >150 ng/mL and carbon monoxide (CO) >12 ppm at intake)
General exclusion criteria:
- psychosis
- presence of acute or unstable medical or neurological illness. Subjects will be excluded from the study if they present with any history of serious medical or neurological illness or if they show signs of a major medical or neurological illness on examination or lab testing including history of seizures, head injury, brain tumor, heart, liver or kidney disease, eating disorder, diabetes.
- regular use of any psychotropic drugs including anxiolytics and antidepressants and other over-the-counter medications and herbal products within the last six months
- pregnancy/Breast feeding (as documented by pregnancy testing at screening or at days of the imaging studies),
- suicidal ideation or behavior
- pacemaker or other ferromagnetic material in body.
- use of medications which affect dopamine transmission within 2 weeks of the PET study
- Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for normal volunteers.
- Blood donation within 8 weeks of the start of the study.
- history of a bleeding disorder or are taking medication to thin their blood
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy Tobacco Smokers
There is only one arm to the study.
All subjects will receive amphetamine
|
Subjects will have 2 PET scans on the same day.
Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
Other Names:
|
Healthy Nonsmokers
There is only one arm to the study.
All subjects will receive amphetamine
|
Subjects will have 2 PET scans on the same day.
Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration
Time Frame: After 2 PET Scans (1 day)
|
Percent change in binding potential of dopamine release during PET scan post amphetamine administration.Binding potential (BP) is the PET neuroimaging outcome measure that is computed as a proxy for availability of dopamine D2/3 receptors in a given region-of-interest.
|
After 2 PET Scans (1 day)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Amphetamine
- Dextroamphetamine
Other Study ID Numbers
- 1106008678
- 1K02DA031750-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Freedom Laser, Inc.NST Consultants, Inc.Completed
-
University of VermontNational Institute of General Medical Sciences (NIGMS)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterCompleted
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence, CigarettesCzechia, Norway
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruiting
-
Duke UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterTerminatedNicotine Dependence, CigarettesUnited States
Clinical Trials on Amphetamine
-
University Hospital, Basel, SwitzerlandCompleted
-
ShireCompletedAttention Deficit Disorder With HyperactivityUnited States
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
University of Illinois at ChicagoThe University of Texas Health Science Center, HoustonRecruiting
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
ShireCompletedAttention Deficit Disorder With Hyperactivity
-
The University of Texas Health Science Center,...Emory UniversityCompleted
-
Noven Pharmaceuticals, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Tris Pharma, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Mayo ClinicLindner Center of HOPERecruiting